HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner

Oncology Letters

Volumn 1, Issue 6, 2010, Pages 1011-1016

  Mizutani, Hideaki ^a   Okano, Tetsuya ^a   Minegishi, Yuji ^a   Matsuda, Kuniko ^a   Sudoh, Junko ^a   Kitamura, Kazuhiro ^a   Noro, Rintaro ^a   Soeno, Chie ^a   Yoshimura, Akinobu ^a   Seike, Masahiro ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Epithelial to mesenchymal transition; HSP27; Lung cancer; Proteomics; Transforming growth factor 1; Two dimensional difference gel electrophoresis

Indexed keywords

HEAT SHOCK PROTEIN 27; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN TISSUE; LUNG CANCER; MASS SPECTROMETRY; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

EID: 77957941995     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.190     Document Type: Article

References (29)

1. Grünert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657-665, 2003.
2. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746, 2003.
3. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
4. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
5. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N and Settleman J: A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500, 2009.
6. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824, 2002.
7. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, KoontzJ, Kratzke R, Watson MA, Kelley M, Ginsburg GS, WestM, Harpole DH Jr and Nevins JR: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New Eng JMed 355: 570-580, 2006.
8. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, ShibataT, Sugimura H, Gemma A, Kudoh S, Wang XW and Harris CC: Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. JNatl Cancer Inst 99: 1257-1269, 2007.
9. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, HorikawaI, Mathe EA, Jen J, Yang P, Sugimura H, GemmaA, Kudoh S, Croce CM and Harris CC: MiR-21 is an EGFR regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 106: 12085-12090, 2009.
10. Saito RA, Watabe T, Horiguchi K, Kohyama T, Saitoh M, Nagase T and Miyazono K: Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res 69: 2783-2791, 2009.
11. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Cancer Res 65: 9455-9462, 2005.
12. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, FuL, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, LinCY, O'Neill V and Amler LC: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698, 2005.
13. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.
14. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14: 7430-7437, 2008.
15. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, BemisL, Gemmill RM, Drabkin HA and Franklin WA: Hirsch tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. JClin Oncol 20: 2417-2428, 2002.
16. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, BeckA and Tan D: Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol 17: 430-439, 2004.
17. Gemma A, Takenaka K, Hosoya Y, Matuda K, Seike M, KurimotoF, Ono Y, Uematsu K, Takeda Y, Hibino S, YoshimuraA, Shibuya M and Kudoh S: Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur JCancer 37: 1554-1561, 2001.
18. Gemma A, Li C, Sugiyama Y, Matsuda K, Minegishi Y, NoroR, Nara M, Seike M, Yoshimura A, Ogawa N, Uesaka H, ShionoyaA, Kawakami A, Kosaihira S and Kudoh S: Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer 6: 174, 2006.
19. Seike M, Kondo T, Mori Y, Gemma A, Kudoh S, Sakamoto M, Yamada T and Hirohashi S: Proteomic analysis of intestinal epithelial cells expressing stabilized beta catenin. Cancer Res63: 4641-4647, 2003.
20. Okano T, Kondo T, Fujii K, Nishimura T, Takano T, OheY, TsutaK, Matsuno Y, Gemma A, Kato H, Kudoh S and HirohashiS: Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 13: 799-805, 2007.
21. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature425: 577-584, 2003.
22. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, Solary E and Garrido C: Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2: 645-652, 2000.
23. Jia Y, Ransom R F, Shibanuma M, Liu C, Welsh MJ and Smoyer WE: Identification and characterization of hic-5/ARA55 as an hsp27 binding protein. JBiol Chem 276: 39911-39918, 2001.
24. Zhuang H, Jiang W, Cheng W, Qian K, Dong W, Cao L, HuangQ, Li S, Dou F, Chiu JF, Fang XX, Lu M and Hua ZC: Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. Lung Cancer 68: 27-38, 2010.
25. Xu L, Chen S and Bergan RC: MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25: 2987-2998, 2006.
26. Jäättelä M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43, 2009.
27. Yao H, Zhang Z, Xiao Z, Chen Y, Li C, Zhang P, Li M, LiuY, Guan Y, Yu Y and Chen Z: Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer 65: 41-48, 2009.
28. Malusecka E, Krzyzowska-Gruca S, Gawrychowski J, Fiszer-Kierzkowska A, Kolosza Z and Krawczyk Z: Stress proteins HSP27 and HSP70i predict survival in non-small cell lung carcinoma. Anticancer Res 28: 501-506, 2008.
29. Berrieman HK, Cawkwell L, O'Kane SL, Smith L and LindMJ: Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer. Oncol Rep 15: 283-286, 2006.